Skip to main content
SpringerLink
Log in

Photoimmunotherapy for Cancer Metastasis Treatment

  • Chapter
  • First Online:
Multifunctional Gold Nanostars for Cancer Theranostics

Part of the book series: Springer Theses ((Springer Theses))

  • 267 Accesses

Abstract

Cancer metastasis has caused more than 90% of cancer deaths (Ferlay J et al in Int J Cancer 136:E359–E386, 2015). When the cancer cells have spread throughout the body, limited therapeutic options, such as systemic chemotherapy, are often not quite effective to control the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386

    Article  CAS  Google Scholar 

  2. Pignon JP, le Maitre A, Maillard E, Bourhis J, Grp M-NC (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14

    Google Scholar 

  3. Van Cutsem E et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

    Article  Google Scholar 

  4. Gebski V et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234

    Article  CAS  Google Scholar 

  5. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909

    Article  CAS  Google Scholar 

  6. Vauthey JN et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072

    Article  CAS  Google Scholar 

  7. Benson AB et al (2004) American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419

    Article  Google Scholar 

  8. Afra D et al (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018

    Article  Google Scholar 

  9. Takahashi H et al (2013) Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era. Eur J Haematol 90:286–290

    Article  CAS  Google Scholar 

  10. Lyford-Pike S et al (2013) Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Can Res 73:1733–1741

    Article  CAS  Google Scholar 

  11. Saresella M, Rainone V, Al-Daghri NM, Clerici M, Trabattoni D (2012) The PD-1/PD-L1 pathway in human pathology. Curr Mol Med 12:259–267

    Article  CAS  Google Scholar 

  12. Zeng Z et al (2011) Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. Plos One 6

    Google Scholar 

  13. Shi F et al (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128:887–896

    Article  CAS  Google Scholar 

  14. Mu C-Y, Huang J-A, Chen Y, Chen C, Zhang X-G (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28:682–688

    Article  CAS  Google Scholar 

  15. Gadiot J, Hooijkaas AI, Kaiser ADM, van Tinteren H, van Boven H, Blank C (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117:2192–2201

    Article  CAS  Google Scholar 

  16. Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19:813–824

    Article  CAS  Google Scholar 

  17. Ghebeh H et al (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia 8:190–198

    Article  CAS  Google Scholar 

  18. Latchman YE et al (2004) PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 101:10691–10696

    Article  CAS  Google Scholar 

  19. Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–4280

    Article  CAS  Google Scholar 

  20. Keir ME, Butte MJ, Freeman GJ, Sharpel AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704

    Article  CAS  Google Scholar 

  21. Hino R et al (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116:1757–1766

    Article  Google Scholar 

  22. Zheng Y-W, Li R-M, Zhang X-W, Ren X-B (2013) Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 31:197–205

    Article  CAS  Google Scholar 

  23. Wolchok JD et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133

    Article  CAS  Google Scholar 

  24. Hamid O et al (2013) Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med 369:134–144

    Article  CAS  Google Scholar 

  25. Liu Y, Maccarini P, Palmer GM, Etienne W, Zhao Y, Lee CT, Ma X, Inman BA, Vo-Dinh T (2017) Synergistic immuno photothermal nanotherapy (SYMPHONY) for the treatment of unresectable and metastatic cancer. Sci Rep 7(8606):1–6

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry, Duke University, Durham, North Carolina, USA

    Yang Liu

Authors
  1. Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yang Liu .

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Liu, Y. (2018). Photoimmunotherapy for Cancer Metastasis Treatment. In: Multifunctional Gold Nanostars for Cancer Theranostics. Springer Theses. Springer, Cham. https://doi.org/10.1007/978-3-319-74920-4_6

Download citation

Publish with us

Policies and ethics

Search

Navigation